AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00960817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Study NCT05434338 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HPV detection test
Description: Samples taken from the squamocolumnar junction using swabs (UTM Copan)
Study NCT05034679 — intervention group
Intervention type: BIOLOGICAL
Intervention: Vcinated
Description: Patients who were vacinated.
Study NCT04575129 — intervention group
Intervention type: OTHER
Intervention: No intervention will be applied
Description: No intervention will be applied
Study NCT05413694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telephone interview 24 months after hospitalization for Covid-19
Description: telephone interview 24 months after hospitalization for Covid-19
Study NCT06006533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: taping
Description: Kinesio taping will be applied in accordance with the fascia correction technique, including the plantar flexor muscles, and it will be requested to stay on the skin for 3 days.
Study NCT06006533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: Percussive Massage will be applied to the posterior part of the sural fascia, including the plantar flexor muscles, 3 times a week for 5 minutes.
Study NCT06486077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Power Line Program
Description: Power Line program consisting of 4 nutritional supplements: a meal replacement shake, a vegetable based green drink, a vascular health product, and a pre-meal fiber supplement
Study NCT05481450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritears®
Description: Strength: Lutein/Zeaxanthin - 20/4 mg; Curcuminoids 200 mg; Vitamin D3 600 IU (Total capsule weight ≈670 mg)
Study NCT05481450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soybean oil capsule (Total capsule weight ≈670 mg)
Study NCT06225752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probucol
Description: Inclusion Days 1-30: Probucol 1000mg/day (500mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.) Inclusion Days 31 and beyond: Probucol 500mg/day (250mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.)
Study NCT05402410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatic venous pressure gradient
Description: All patients underwent measurement of HVPG under local anesthesia.
Study NCT05923619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total pulpotomy
Description: Total pulpotomy procedures explained in arm descriptions.
Study NCT05923619 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment
Description: Root canal treatment procedures explained in arm descriptions.
Study NCT05745194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of adherence to the MedDiet
Description: Participants will be followed in six individual nutrition consultations with a duration of 30 to 60 minutes. The consultations will be focused on promoting the adherence to the MedDiet.~The nutritional intervention will be personalized to each individual ad libitum, without calories or macronutrients restriction and without the goal to promote weight change. The intervention will begin with an initial assessment of the dietary patterns of the participants in which the nutritionist will identify potential behavioural changes to promote adjustments in dietary habits and therefore adherence to the MedDiet.~The intervention will promote positive recommendations (behaviours recommended to follow) and negative recommendations (behaviours recommended to reduce or eliminate) (26), using the strategy and MedDiet definition proposed by Estruch et al. in the Primary Prevention of Cardiovascular Disease with a Mediterranean Diet study (3).~The participants will also maintain MDD TAU.
Study NCT06225752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo probucol
Description: Inclusion Days 1-30: Placebo Probucol 1000mg/day (500mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.) Inclusion Days 31 and beyond: Placebo Probucol 500mg/day (250mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.)
Study NCT06491329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-intensity interval training
Description: high-intensity interval training ： 40-50 minutes, patients engage in power cycling with intervals of high-intensity exercise at 75%-100% of VO2peak for 30s-1min, followed by 30s-1min of passive recovery, totaling 15-25 cycles.
Study NCT06491329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate-intensity interval training
Description: 40-50 minutes, involves power cycling with 8 minutes of moderate-intensity exercise at 40%-60% of VO2peak followed by 2 minutes of passive recovery, totaling 4 cycles.
Study NCT06488443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Participants in yoga arm will receive intervention from an instructor who would be trained in the intervention by the yoga adviser.All the yoga exercises selected for this study are low-impact and involve highly controlled movements. All yoga exercises will be taught and supervised by a skilled yoga-instructor. The yoga-instructor will take great care to emphasize to participants that they should not go beyond their usual range of motion/comfort for any of the yoga exercises.
Study NCT06488443 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WHO 5As model intervention
Description: WHO 5As model to help patients ready to quit. The five major steps to intervention are the 5 A's: Ask, Advise, Assess, Assist, and Arrange.
Study NCT05737225 — intervention group
Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy (NIRS)
Description: We will place Near Infrared Spectroscopy (NIRS) electrode on the foot to evaluate regional tissue oxygen saturation in both lower extremities before the performing regional anesthesia (popliteal sciatic nerve block) and then during the procedure.
Study NCT05555940 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: The stimulation sites of the true TMS group were mPFC-amygdala functional junction and SSRIs/SNRIs treatment, while the sham TMS group was treated with reversed magnetic head sham stimulation and SSRIs/SNRIs treatment.
Study NCT05555940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: The stimulation sites of the true TMS group were mPFC-amygdala functional junction and SSRIs/SNRIs treatment, while the sham TMS group was treated with reversed magnetic head sham stimulation and SSRIs/SNRIs treatment.
Study NCT06247527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation, Relaxation, PrOblem solving, Activation, Cognitive coping Therapy
Description: This is a brief transdiagnostic psychological intervention based on the trauma-focused cognitive behavioral therapy (TF-CBT) designed for delivery by non-specialist providers to adolescents and youth with psychological distress
Study NCT06247527 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Any intervention, including counseling, provided as a routine intervention at the HIV clinic selected as a control clinic
Study NCT06072209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: - instruction to create a list of individual positive activities. - instruction to include daily positive activities and fill out a mood protocol, which covers the time period shortly before, during and after the activity.
Study NCT06072209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and Gratitude
Description: - instruction to fill out a mindfulness diary: reflection of daily pleasant situation, instructing the participants to revisit the impressions of their 5 senses during this situation, in addition they should specify how long they have actually dealt with
Study NCT06072209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination of Behavioral Activation and Mindfulness and Gratitude
Description: This group will do a combination of the two intervention types.
Study NCT05483998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC-2716
Description: TLC-2716
Study NCT05483998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match
Study NCT04937270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency therapy (5 minutes)
Description: The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 5 minutes using a 500 kHz resistive electric transfer (RET).
Study NCT05911646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OSA-18 Survey
Description: OSA 18 is an 18-item questionnaire that uses a Likert-type scoring system to collect information about 5 subscales that are considered to be elements in quality of life: sleep disturbance, physical symptoms, emotional symptoms, daytime function, and caregiver concerns. On the basis of this information, a summary score is calculated and scores are divided into three categories:~Mild (40-60), moderate (61-80) and severe >81.
Study NCT05911646 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decisional Conflict (DCS)
Description: The DCS is a 16-item survey in which participants are asked to respond to statements related to their decision on a five-point ordinal Likert scale: 0) strongly agree, 1) agree, 2) neither agree nor disagree, 3) disagree, and 4) strongly disagree. Scores are summed, divided by 16, and multiplied by 25. Scores range from 0, signifying that the respondent has complete certainty about the best choice, to 100, which signifies that the respondent feels extremely uncertain about the best choice.
Study NCT05911646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decisional Conflict (DCS)
Description: The DCS is a 16-item survey in which participants are asked to respond to statements related to their decision on a five-point ordinal Likert scale: 0) strongly agree, 1) agree, 2) neither agree nor disagree, 3) disagree, and 4) strongly disagree. Scores are summed, divided by 16, and multiplied by 25. Scores range from 0, signifying that the respondent has complete certainty about the best choice, to 100, which signifies that the respondent feels extremely uncertain about the best choice.
Study NCT06102746 — intervention group
Intervention type: DRUG
Intervention: Sintilimab，Surufatinib
Description: Based on the standard EP regimen, the combination of surufatinib (anti-angiogenic therapy) and sintilimab (PD-1 inhibitor) were used among patients with advanced gastric neuroendocrine carcinoma.
Study NCT06575530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sedation drug
Description: this non inferiority study is to evaluate the efficiency and safety of rimazolen benzenesulfonate campare with dexmedetomidine, the sedation drug dosage is titrate with the depth of sedation evaluated with RASS score(0\~ -3)
Study NCT06575530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sedation drug
Description: this non inferiority study is to evaluate the efficiency and safety of rimazolen benzenesulfonate campare with dexmedetomidine, the sedation drug dosage is titrate with the depth of sedation evaluated with RASS score(0\~ -3)
Study NCT05821517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helmet virtual reality.
Description: Use of a  virtual reality  (VR) headset of  Pico G2  type with  HypnoVR  software and audio headset  Taotronics BH22  during all the reduction care
Study NCT05821517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of METHOXYFLURANE
Description: Self administered inhalated methoxyflurane (maximal inhaled dose : 3 mL)
Study NCT05821517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: An anticipated analgesia protocol composed of PARACETAMOL 1g +/- OXYNORM 5 mg or 10 mg according to patients weight and pain intensity as evaluated by a simple numeric rating scale is administred prior to the reduction procedure. Inhaled equimolar mixture of oxygen and notrous oxyde (MEOPA) at a 15L/min flux is administered concomitantly to the reduction procedure.
Study NCT04866940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequences test
Description: the realization of preliminary acquisitions to validate the feasibility of clinical or cognitive research protocols
Study NCT05800730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: refined carbohydrate breakfast
Description: After wearing CGM on Day 1, participants will be provided with breakfast A once daily on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12. Breakfast A contains white bread (50g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
Study NCT05800730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole grain breakfast
Description: After wearing CGM on Day 1, participants will be provided with Breakfast B once daily on Day 5, Day 6, Day 9, Day 11. Breakfast B contains plain oats (35g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
Study NCT05800730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: energy-restricted diet
Description: After completing the baseline data and biological sample collection, the ERD group volunteers underwent a 10-day dietary intervention from day 3 to day 12. During this period, a standard breakfast was provided to all volunteers daily by the research staff through the school cafeteria. The ERD group volunteers still had their lunch and dinner provided by the research staff through the school cafeteria to ensure their daily energy intake was controlled between 1200-1500 kcal.
Study NCT05800730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: time-restricted diet
Description: After completing the baseline data and biological sample collection, the volunteers in the TRD group will undergo a 10-day dietary intervention from day 3 to day 12. The TRD group needs to adjust their breakfast eating time to after 10:00 am daily, and they are free to choose their own lunch and dinner according to their dietary habits but must finish their meals before 4:00 pm. During this time window, no other energy-providing foods should be consumed.
Study NCT05053451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, saline-soaked electrodes are temporarily affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (20 minutes) to stimulate the targeted brain area (e.g. the DLPFC, TPJ, Occipital Cortex) depending on the phase of the study.
Study NCT05411094 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT04937270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency therapy (7 minutes)
Description: The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 7 minutes using a 500 kHz resistive electric transfer (RET).
Study NCT04937270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency therapy (9 minutes)
Description: The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 9 minutes using a 500 kHz resistive electric transfer (RET).
Study NCT05009212 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic stricturotomy
Description: Endoscopic stricturotomy for bowel stricture (\<5 cm)
Study NCT05411094 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and buccal samples
Study NCT05009212 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic balloon dilatation
Description: Endoscopic balloon dilatation for bowel stricture (\<5 cm)
Study NCT04937270 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Superficial heat therapy
Description: In the physical therapy used in this study, it was applied for 20 minutes using conventionally used superficial heat therapy.
Study NCT05467085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BX Pulsar 1002
Description: Imaging-Guided Low Intensity Focused Ultrasound Pulsation (LIFU) device
Study NCT05012566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvederm
Description: * Juvederm Volbella: 15mg/ml, it is injected 1.5ml per patient per treatment (a total of 3ml per patient split in 2 treatment sessions at a 4 months interval);~* Juvederm Volifit: 17.5mg/ml, it is injected 3ml per patient per treatment (a total of 6ml per patient split in 2 treatment sessions at a 4 months interval);~* Juvederm Voluma: 20mg/ml, it is injected 5ml per patient per treatment (a total of 10ml per patient split in 2 treatment sessions at a 4 months interval)
Study NCT05012566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vistabex
Description: Vistabex: 50U/vial, it is injected up to 80U per patient per treatment (2 treatment sessions at a 4 months interval)
Study NCT05411094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT05411094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT05411094 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT05411094 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiologic Examination
Description: Undergo radiologic evaluation
Study NCT06186765 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Axonics SNM System (Model 4101)
Description: Safety and performance/effectiveness assessment of the recharge free Axonics SNM System (Model 4101 in participants with overactive bladder (OAB) or fecal incontinence (FI).
Study NCT05418374 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continous Spinal Anestheisa
Description: Continuous spinal anesthesia (CSA) describes subarachnoid blockade maintained by local anesthetics administered through an indwelling spinal catheter. CSA provides fewer episodes of hypotension and no severe hypotension versus single dose bupivacaine also it offers the ability to titrate the dose of local anesthetics needed while maintaining hemodynamic stability.
Study NCT04966299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eryhtritol
Description: Eryhtritol-sweetened beverages twice a day (36g erythritol/day) with main meals during 5 weeks~EryClot-Pilot:~Erythritol 50g dissolved in 300mL water administered once per visit~EryClot:~Erythritol 50g dissolved in 300mL water administered once per visit
Study NCT04966299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: Sucrose-sweetened beverages twice a day (25g sucrose/day) with main meals during 5 weeks
Study NCT04966299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Glucose 75g dissolved in 300mL water administered once per visit
Study NCT04966299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fructose
Description: Fructose 25g dissolved in 300mL water administered once per visit
Study NCT04966299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Xylitol
Description: Xylitol 33.5g dissolved in 300mL water administered once per visit
Study NCT04966299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 300mL water administered once per visit
Study NCT06202755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90 MG
Description: Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study NCT06202755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 100 MG
Description: Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study NCT06561984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: antenatal education
Description: Giving educational sessions to the intervention group regarding modes of delivery
Study NCT04631562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1820 SC
Description: ALXN1820 SC will be administered as a manual SC push or SC infusion via a syringe pump. Doses will range from 12.5 milligrams (mg) to a maximum of 2250 mg. Multiple dosing duration will range from 3 to 5 weeks.
Study NCT06574035 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Cognitive behavioral therapy focuses on the unique needs of men. A culturally adapted CBT program will be administered to participants as it has demonstrated increased effectiveness for marginalized populations. Cognitive Behavioral Therapy (CBT) aligns well with these cultural needs due to its individualized approach, non-judgmental stance, collaborative nature, and emphasis on empowerment through skills building.